Antimicrobial resistance (AMR) poses a significant threat to modern medicine, rapidly advancing on a global scale. Pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Enterobacteriaceae, and drug-resistant gonorrhea undermine the advances of medicine. As the production of new antibiotics stalls, novel approaches such as artificial intelligence (AI)-driven discovery, teixobactin, a compound drawn from soil, and phage therapy create a ray of hope.
While antibiotics revolutionized the field of medicine in the 20th century, increasing life expectancy and child survival rates, they also brought about unique challenges. The AMR is the most pressing of these. It poses a significant threat, with predictions from the World Health Organization suggesting that AMR could result in around 10 million global deaths yearly by 2050, surpassing even the mortality rate of cancer.
Hospitals are increasingly confronted with the rise of ‘superbugs’ likes methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae. These bacteria make routine procedures potentially life-threatening. Cases of ‘super gonorrhea,’ caused by multidrug-resistant Neisseria gonorrhoeae, are also increasing. Gonorrhea, once easily treatable with penicillin, has now become resistant to first cephalosporins, and now ceftriaxone, the last chosen line of treatment.
The pharmaceutical industry has struggled to keep pace with the evolving superbugs. For nearly 30 years, from 1987 to 2017, no new types of antibiotics were discovered. The last class, oxazolidinones, was only approved in 2020. Consequently, clinicians have shifted to using modified existing antibiotics, which proved not very effective against these superbugs.
A paradigm shift is underway with researchers finding potential solutions in overlooked fields such as soil bacteria and AI-driven design. The discovery of Teixobactin from Eleftheria Terrae and Murayamycin from soil bacteria, Lugdunin from human nose staph, hold promise in combating AMR. The application of AI has also shown promise, as depicted in the development of Halicin and Abaucin by researchers at MIT and Harvard. These AI-derived drugs effectively target a wide range of drug-resistant bacteria.
Phage therapy presents an alternative solution. Some engineered viruses, like Armata’s AP-PA02, can kill resistant Pseudomonas. Hence, this resurgence in antibiotic research provides a beacon of hope in overcoming AMR. To effectively combat AMR, we require an integrated strategy that includes drug development, stewardship, diagnostics, microbiome testing, pharmacological surveillance incorporating AI and genomic surveillance, and overall, a global collaborative effort.